Human PET research does not provide one uniform finding of elevated inflammation-related binding after methamphetamine use. An influential 2008 study reported substantially increased binding, while two later studies did not find a significant overall group elevation. The disagreement is scientifically useful because these experiments measured different tracers and populations using different analytical models.
What is TSPO imaging measuring?
The 18-kDa translocator protein, or TSPO, is used as a target for PET radiotracers in research on neuroinflammation. It is not exclusive to activated microglia: astrocytes and vascular cells can also contribute. A tracer signal is therefore not equivalent to directly counting activated microglia in tissue.
Neither a positive nor a null TSPO comparison measures every form of inflammation. The studies are observational human comparisons, not experiments assigning chronic methamphetamine exposure, and none establishes a standalone test of an individual’s brain injury or functioning.
What did the 2008 study find?
Sekine and colleagues compared twelve abstinent methamphetamine users with twelve matched controls using [11C](R)-PK11195. Abstinence ranged from six months to four years. Binding potential was significantly higher in all five examined brain regions.
Longer abstinence correlated with lower binding in several regions; the midbrain, striatum and thalamus associations met the paper’s stricter multiple-testing threshold. This was a comparison between people with different abstinence histories, not serial scans demonstrating recovery within the same people.
The model used a normalized time–activity curve derived from control cortical regions as a reference input for both groups. That methodological choice became one focus of later discussion. Although the paper’s title used causal language, the human exposure comparison itself remained observational.
What happened with a different tracer in early abstinence?
London and colleagues’ 2020 study used [11C]DAA1106 in eleven methamphetamine-dependent participants and twelve controls, as specified in its methods and participant table. Abstinence ranged from four days to twenty-four weeks, with a median of six days. All participants were daily cigarette smokers and high-affinity TSPO binders under the study’s genotype selection.
The investigators used standardized uptake values, normalized to injected radioactivity and body weight. Whole-brain uptake did not differ significantly (p=0.363), although regional means were numerically higher in the methamphetamine group. This was a null significance test, not proof of identical binding.
The paper acknowledged that the uptake measure had not been validated against a full kinetic model for this application. Small sample size, smoking selection and the much earlier abstinence window also limited direct comparison with the 2008 findings.
What did arterial-input modeling add?
Rathitharan and colleagues studied eleven actively using participants and twenty-six controls with [18F]FEPPA. Their paper appeared online in 2020 and in the 2021 volume of Addiction Biology. They estimated regional distribution volume using a two-tissue compartment model with arterial plasma input and accounted for TSPO binding genotype.
The study found no significant main group elevation. Reported last use was fourteen to 110 hours before scanning, and ten of eleven participants had detectable methamphetamine in blood. These conditions differ substantially from sustained abstinence.
There were exploratory regional and use-frequency signals. Frequency correlations did not survive correction for multiple comparisons, and the small daily-use subgroup required caution. Those observations should neither be omitted nor recast as confirmation of a large global increase.
Can the discrepancy identify a single explanation?
Not yet. Tracer properties, reference modeling, uptake versus distribution-volume outcomes, smoking, other drug exposure, genotype and abstinence duration all differed. Comparing these separate studies cannot isolate the effect of any one difference.
The null studies were small and could miss more modest effects. Conversely, one large relative difference in a small early study does not establish a universally reproducible biomarker. TSPO’s cellular nonspecificity constrains both interpretations.
The evidence supports a question requiring further longitudinal and methodological work. It does not support treating all PET markers as interchangeable, concluding that inflammation has been disproved, or assigning a specific person’s symptoms to methamphetamine from a scan alone.
Sources
- Sekine Y, Ouchi Y, Sugihara G, et al. Methamphetamine Causes Microglial Activation in the Brains of Human Abusers. Journal of Neuroscience. 2008;28(22):5756–5761. doi:10.1523/JNEUROSCI.1179-08.2008.
- London ED, Okita K, Kinney KR, et al. No significant elevation of translocator protein binding in the brains of recently abstinent methamphetamine users. Drug and Alcohol Dependence. 2020;213:108104. doi:10.1016/j.drugalcdep.2020.108104.
- Rathitharan G, Truong J, Tong J, et al. Microglia imaging in methamphetamine use disorder: a positron emission tomography study with the 18-kDa translocator protein radioligand [F-18]FEPPA. Addiction Biology. 2021;26(1):e12876; online 2020. doi:10.1111/adb.12876.
Leave a Reply